OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Medicine is 180. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	3079
Post-acute COVID-19 syndrome	2973
Extrapulmonary manifestations of COVID-19	2191
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections	2182
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19	2009
A global survey of potential acceptance of a COVID-19 vaccine	1810
An inflammatory cytokine signature predicts COVID-19 severity and survival	1779
Attributes and predictors of long COVID	1581
A serological assay to detect SARS-CoV-2 seroconversion in humans	1521
Age-dependent effects in the transmission and control of COVID-19 epidemics	1291
A single-cell atlas of the peripheral immune response in patients with severe COVID-19	1228
Real-time tracking of self-reported symptoms to predict potential COVID-19	1099
Long-term cardiovascular outcomes of COVID-19	1057
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	825
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	822
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	768
A dynamic COVID-19 immune signature includes associations with poor prognosis	718
AI in health and medicine	709
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19	687
Digital technologies in the public-health response to COVID-19	684
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	664
Seasonal coronavirus protective immunity is short-lasting	587
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	586
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	536
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	535

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma	509
SARS-CoV-2 infection of the oral cavity and saliva	508
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	486
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	484
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	483
Immune determinants of COVID-19 disease presentation and severity	481
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong	472
Targeting metastatic cancer	472
Determinants of COVID-19 disease severity in patients with cancer	466
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	460
Long COVID after breakthrough SARS-CoV-2 infection	456
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	455
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda	452
Single-cell multi-omics analysis of the immune response in COVID-19	446
Looking beyond COVID-19 vaccine phase 3 trials	444
Long COVID in a prospective cohort of home-isolated patients	438
Symptoms and risk factors for long COVID in non-hospitalized adults	433
Understanding COVID-19 vaccine hesitancy	430
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	429
Infection of bat and human intestinal organoids by SARS-CoV-2	427
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	425
Human postprandial responses to food and potential for precision nutrition	421
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	418
Biomarkers for neurodegenerative diseases	416
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein	414
Intratumoral heterogeneity in cancer progression and response to immunotherapy	397
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors	394
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	387
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	385
Human–computer collaboration for skin cancer recognition	384
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	382
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	372
Toward personalized treatment approaches for non-small-cell lung cancer	368
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	366
Deep learning in histopathology: the path to the clinic	366
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes	363
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	363
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	362
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	360
A deep learning system for differential diagnosis of skin diseases	359
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19	355
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension	350
Partial recovery of visual function in a blind patient after optogenetic therapy	346
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	345
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	343
Brown adipose tissue is associated with cardiometabolic health	337
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	337
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	337
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	337
Disease and healthcare burden of COVID-19 in the United States	336

Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	336
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	331
Modeling COVID-19 scenarios for the United States	327
Large language models in medicine	326
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	324
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	323
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	323
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China	321
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	319
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis	314
Sixteen novel lineages of SARS-CoV-2 in South Africa	314
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	312
Federated learning for predicting clinical outcomes in patients with COVID-19	310
Wearable sensor data and self-reported symptoms for COVID-19 detection	310
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection	308
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	307
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	299
SARS-CoV-2 variants of concern are emerging in India	297
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle	297
Cellular senescence and senolytics: the path to the clinic	296
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors	296
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial	295
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	295
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial	290
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	285
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	283
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	282
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	281
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	280
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	269
A single-cell landscape of high-grade serous ovarian cancer	268
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	268
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	267
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist	267
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling	266
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters	265
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	263
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease	262
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	258
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	256
Targeting the HIF2–VEGF axis in renal cell carcinoma	255
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	251
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	250
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade	248
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	248
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	246
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	243
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection	242
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands	242
Unexplained post-acute infection syndromes	242
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	241
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension	241
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	238
A stochastic agent-based model of the SARS-CoV-2 epidemic in France	238
Microglial activation and tau propagate jointly across Braak stages	238
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	237
Long-term neurologic outcomes of COVID-19	236
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	234
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	233
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	229
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	226
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	224
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	220
Multimodal biomedical AI	219
Vaccine development for emerging infectious diseases	217
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	215
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	214
Closed-loop neuromodulation in an individual with treatment-resistant depression	214
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	213
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	213
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	213
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	212
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	212
A guide to immunotherapy for COVID-19	211
The distribution of cellular turnover in the human body	209
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring	209
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	207
A roadmap to increase diversity in genomic studies	206
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	205
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	204

Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	203
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	201
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	198
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies	197
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	197
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer	196
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	196
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	195
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models	195
Articular cartilage regeneration by activated skeletal stem cells	195
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	194
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	194
Crowding and the shape of COVID-19 epidemics	192
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	191
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma	191
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	190
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study	189
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	188
Increased global integration in the brain after psilocybin therapy for depression	185
Using a real-world network to model localized COVID-19 control strategies	184
Modeling shield immunity to reduce COVID-19 epidemic spread	183
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	182
Modeling transmission of SARS-CoV-2 Omicron in China	181
Global maps of travel time to healthcare facilities	180
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease	180